Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles | Zendy

Sanya J Thomas | Zendy; Jacob T Kilgore | Zendy; Bradford Becken | Zendy; Coleen K. Cunningham | Zendy; Amelia B. Thompson | Zendy

Open Access

Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles

Author(s) -

Sanya J Thomas,

Jacob T Kilgore,

Bradford Becken,

Coleen K. Cunningham,

Amelia B. Thompson

Publication year - 2020

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piaa089

Subject(s) - raltegravir , medicine , human leukocyte antigen , eosinophilia , hla b , immunology , regimen , drug , antigen , human immunodeficiency virus (hiv) , virology , pharmacology , antiretroviral therapy , viral load

We present the first published case of raltegravir-associated drug-reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a child without characteristic human leukocyte antigen haplotypes HLA-B*57:01 or HLA-B*53:01. A 4-year-old African American female with perinatally acquired human immunodeficiency virus infection was hospitalized for DRESS after starting a raltegravir-based antiretroviral regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research